All Stories

  1. Peer victimization in adolescence alters gene expression and cytokine profiles during transition to adulthood
  2. The role of astrocytes in attention-deficit hyperactivity disorder: An update
  3. Assessing the effects of methylphenidate in proliferation and Wnt activity of neuronal stem cells from attention deficit/hyperactivity disorder patients
  4. Polygenic Hazard Score for Predicting Age-associated Risk of Alzheimer’s Disease in European Populations: Development and Validation
  5. Machine learning in Alzheimer’s disease genetics
  6. The link between Wnt-related, stress-related, and circadian genes in the dermal fibroblasts of individuals with attention-deficit hyperactivity disorder
  7. Approaching therapy of Alzheimer’s disease via the antidiabetic drug liraglutide—a study with streptozotocin intracerebroventricularly treated Wistar rats
  8. Thiamine Compounds Alleviate Oxidative Stress, Over-Expression of Pro-Inflammatory Markers and Behavioral Abnormalities in a Mouse Predation Model of PTSD
  9. Ensemblex: an accuracy-weighted ensemble genetic demultiplexing framework for population-scale scRNAseq sample pooling
  10. From stress to anhedonia: differential gene expression, behavioural and biochemical modulations in resilient versus susceptible mice in an ultrasound model of juvenile depression
  11. Transferability of European-derived Alzheimer’s disease polygenic risk scores across multiancestry populations
  12. Genome-wide analyses identify 30 loci associated with obsessive–compulsive disorder
  13. APOEstratified genome-wide association studies provide novel insights into the genetic etiology of Alzheimers’s disease
  14. Genetic susceptibility to schizophrenia through neuroinflammatory pathways associated with retinal thinness
  15. Neurodevelopmental effects of omega-3 fatty acids and its combination with Methylphenidate in iPSC models of ADHD
  16. Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial
  17. Alterations in proliferation of neuronal stem cells in Attention-Deficit/Hyperactivity Disorder and Wnt modulation by methylphenidate
  18. Exploring the interplay of glucose metabolism, insulin resistance, and neurodegenerative pathologies: insights from streptozotocin and hypoglycaemic in vitro models
  19. Investigating the impact of omega-3 fatty acids on oxidative stress and pro-inflammatory cytokine release in iPSC-derived forebrain cortical neurons from ADHD patients
  20. X‐chromosome-wide association study for Alzheimer’s disease
  21. Generation of induced pluripotent stem cells from ADHD patients who do or do not respond to Methylphenidate treatment
  22. Extremely rare CNVs contributing to Alzheimer disease risk: a case-control association analysis of exome sequencing data from 22,319 individuals
  23. Peer victimization in adolescence alters gene expression and cytokine profiles during transition to adulthood
  24. A genome‐wide association meta‐analysis of all‐cause and vascular dementia
  25. Ensemblex: an accuracy-weighted ensemble genetic demultiplexing framework for population-scale scRNAseq sample pooling
  26. Ensemblex: an accuracy-weighted ensemble genetic demultiplexing framework for population-scale scRNAseq sample pooling
  27. Correspondence to “Bipolar disorder-iPSC derived neural progenitor cells exhibit dysregulation of store-operated Ca2+ entry and accelerated differentiation” by Hewitt et al. (PMID: 37402854)
  28. Long non-coding RNAs H19 and NKILA are associated with the risk of death and lacunar stroke in the elderly population
  29. Genetic susceptibility to schizophrenia through neuroinflammatory pathways is associated with retinal thinning: Findings from the UK-Biobank
  30. Stress as a mediator of brain alterations in attention-deficit hyperactivity disorder: A systematic review
  31. Genome-wide analyses identify 30 loci associated with obsessive-compulsive disorder
  32. Correction: White matter diffusion estimates in obsessive-compulsive disorder across 1653 individuals: machine learning findings from the ENIGMA OCD Working Group
  33. White matter diffusion estimates in obsessive-compulsive disorder across 1653 individuals: machine learning findings from the ENIGMA OCD Working Group
  34. Psychopharmacology in children and adolescents: unmet needs and opportunities
  35. Iron status in Swiss adolescents with paediatric major depressive disorder and healthy controls: a matched case–control study
  36. Polygenic risk for Alzheimer's disease is associated with neuroaxonal damage before onset of clinical symptoms
  37. An investigation on the alterations in Wnt signaling in ADHD across developmental stages
  38. Is there an intrinsic link between attention-deficit/hyperactivity disorder and Alzheimer's disease? Examination using polygenic risk scores in the UK Biobank
  39. Transferability of European-derived Alzheimer’s Disease Polygenic Risk Scores across Multi-Ancestry Populations
  40. Editorial: Obsessive-compulsive related disorders (OCRD) across the lifespan
  41. Multiancestry analysis of the HLA locus in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes
  42. Executive functions and borderline personality features in adolescents with major depressive disorder
  43. The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications
  44. Generation of induced pluripotent stem cells from two ADHD patients and two healthy controls
  45. Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease
  46. Circulating Long Noncoding RNA Signatures Associate With Incident Diabetes in Older Adults: A Prospective Analysis From the VITA Cohort Study
  47. Circulating long noncoding RNA signatures associate with incident diabetes in older adults: a prospective analysis from the VITA cohort study
  48. Circulating long noncoding RNA signatures associate with incident diabetes in older adults: a prospective analysis from the VITA cohort study
  49. Growth rates of human induced pluripotent stem cells and neural stem cells from attention-deficit hyperactivity disorder patients: a preliminary study
  50. From attention-deficit hyperactivity disorder to sporadic Alzheimer’s disease—Wnt/mTOR pathways hypothesis
  51. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
  52. Elucidating the functional effects of omega-3 fatty acids as a treatment in ADHD against inflammation and oxidative stress
  53. Involvement of the WNT signalling in methylphenidate (ritalin) treatment of attention deficit hyperactivity disorder
  54. Protocol for a Wnt reporter assay to measure its activity in human neural stem cells derived from induced pluripotent stem cells
  55. Recommendations, guidelines, and best practice for the use of human induced pluripotent stem cells for neuropharmacological studies of neuropsychiatric disorders
  56. Advances in problematic usage of the internet research – A narrative review by experts from the European network for problematic usage of the internet
  57. A review of the genetic basis of problematic Internet use
  58. Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease
  59. Protective association of HLA-DRB1*04 subtypes in neurodegenerative diseases implicates acetylated tau PHF6 sequences
  60. Brain-derived neurotrophic factor protects serotonergic neurons against 3,4-methylenedioxymethamphetamine (“Ecstasy”) induced cytoskeletal damage
  61. New insights into the genetic etiology of Alzheimer’s disease and related dementias
  62. Media use and emotional distress under COVID-19 lockdown in a clinical sample referred for internalizing disorders: A Swiss adolescents' perspective
  63. Problematic use of the internet during the COVID-19 pandemic: Good practices and mental health recommendations
  64. Promising Developments in the Use of Induced Pluripotent Stem Cells in Research of ADHD
  65. Elucidating the functional effects of omega-3 fatty acids as a treatment in ADHD against Wnt-signalling alterations
  66. Protective association of HLA-DRB1*04 subtypes in neurodegenerative diseases implicates acetylated Tau PHF6 sequences
  67. P.0006 BDNF levels in blood serum and plasma of MDMA users and MDMA-naïve controls
  68. P.0025 Preliminary results of growth rate profiling of induced pluripotent stem cells and neuronal progenitor cells from Attention-Deficit Hyperactivity Disorder
  69. Polygenic risk scores across the extended psychosis spectrum
  70. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects
  71. Genome-wide association study identifies new locus associated with OCD
  72. Media use before, during and after COVID-19 lockdown according to parents in a clinically referred sample in child and adolescent psychiatry: Results of an online survey in Switzerland
  73. Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores
  74. Generation of integration-free induced pluripotent stem cell lines from four pediatric ADHD patients
  75. Generation of integration-free induced pluripotent stem cells from healthy individuals
  76. The Interplay Between Postsynaptic Striatal D2/3 Receptor Availability, Adversity Exposure and Odd Beliefs: A [11C]-Raclopride PET Study
  77. Genome-wide association study of pediatric obsessive-compulsive traits: shared genetic risk between traits and disorder
  78. Genetics of OCD and Related Disorders; Searching for Shared Factors
  79. New insights on the genetic etiology of Alzheimer’s and related dementia
  80. The stress–Wnt-signaling axis: a hypothesis for attention-deficit hyperactivity disorder and therapy approaches
  81. Preventing problematic internet use during the COVID-19 pandemic: Consensus guidance
  82. ADHD: Current Concepts and Treatments in Children and Adolescents
  83. Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders
  84. An overview of the first 5 years of the ENIGMA obsessive–compulsive disorder working group: The power of worldwide collaboration
  85. Psychiatric symptoms and expression of glucocorticoid receptor gene in cocaine users: A longitudinal study
  86. Profiling parvalbumin interneurons using iPSC: challenges and perspectives for Autism Spectrum Disorder (ASD)
  87. Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings
  88. Genetics of obsessive-compulsive disorder and Tourette disorder
  89. High-resolution chromosomal microarray analysis for copy-number variations in high-functioning autism reveals large aberration typical for intellectual disability
  90. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders
  91. Genome-wide Association Study of Pediatric Obsessive-Compulsive Traits: Shared Genetic Risk between Traits and Disorder
  92. Omega-3 Fatty Acids as a Treatment for Pediatric Depression. A Phase III, 36 Weeks, Multi-Center, Double-Blind, Placebo-Controlled Randomized Superiority Study
  93. Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brain‐related functional pathways
  94. Common variants in Alzheimer's disease: Novel association of six genetic variants with AD and risk stratification by polygenic risk scores
  95. Influence of oxytocin receptor single nucleotide sequence variants on contractility of human myometrium: an in vitro functional study
  96. New insights and perspectives on the genetics of obsessive-compulsive disorder
  97. No Association of Variants of the NPY-System With Obsessive-Compulsive Disorder in Children and Adolescents
  98. Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice
  99. Association study and a systematic meta-analysis of the VNTR polymorphism in the 3′-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder
  100. Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity – a consensus of the Biomarkers Task Force from the WFSBP
  101. Astrocyte- and Microglia-Specific Mitochondrial DNA Deletions Levels in Sporadic Alzheimer’s Disease
  102. The involvement of the canonical Wnt-signaling receptor LRP5 and LRP6 gene variants with ADHD and sexual dimorphism: Association study and meta-analysis
  103. Manifesto for a European research network into Problematic Usage of the Internet
  104. Improved Generation of Induced Pluripotent Stem Cells From Hair Derived Keratinocytes – A Tool to Study Neurodevelopmental Disorders as ADHD
  105. Comment on the global gaming industry's statement on ICD-11 gaming disorder: a corporate strategy to disregard harm and deflect social responsibility?
  106. Glucocorticoid receptor gene variants and lower expression of NR3C1 are associated with cocaine use
  107. Neuregulin 1 (NRG1) gene expression predicts functional outcomes in individuals at clinical high-risk for psychosis
  108. Methylphenidate enhances neuronal differentiation and reduces proliferation concomitant to activation of Wnt signal transduction pathways
  109. Neurochemical markers as potential indicators of postmortem tissue quality
  110. Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits
  111. Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson’s Disease Substantia Nigra
  112. A pilot investigation on DNA methylation modifications associated with complex posttraumatic symptoms in elderly traumatized in childhood
  113. High resolution chromosomal microarray analysis in paediatric obsessive-compulsive disorder
  114. Controversial Effects of D-Amino Acid Oxidase Activator (DAOA)/G72 on D-Amino Acid Oxidase (DAO) Activity in Human Neuronal, Astrocyte and Kidney Cell Lines: The N-methyl D-aspartate (NMDA) Receptor Hypofunction Point of View
  115. Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder
  116. Explorative results from multistep screening for potential genetic risk loci of Alzheimer’s disease in the longitudinal VITA study cohort
  117. The impact of methylphenidate and its enantiomers on dopamine synthesis and metabolism in vitro
  118. Combining genetic and epigenetic parameters of the serotonin transporter gene in obsessive-compulsive disorder
  119. A systematic meta-analysis of the association of Neuregulin 1 (NRG1), d-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia
  120. Effects of oxytocin and arginine vasopressin on the proliferation and differentiation of a serotonergic cell line
  121. The diabetic brain and cognition
  122. Revealing the complex genetic architecture of obsessive–compulsive disorder using meta-analysis
  123. Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease
  124. A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects
  125. Emerging role of miRNA in attention deficit hyperactivity disorder: a systematic review
  126. Expression of D-Amino Acid Oxidase (DAO/DAAO) and D-Amino Acid Oxidase Activator (DAOA/G72) during Development and Aging in the Human Post-mortem Brain
  127. The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension
  128. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson’s disease
  129. Neuregulin-1, D-amino acid oxidase and D-amino acid oxidase activator polymorphisms in individuals at-risk for psychosis
  130. DNA methylation profiles of elderly individuals subjected to indentured childhood labor and trauma
  131. Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms
  132. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition
  133. Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics
  134. REGION-SPECIFIC REGULATION OF THE SEROTONIN 2A RECEPTOR EXPRESSION IN DEVELOPMENT AND AGING IN POSTMORTEM HUMAN BRAIN
  135. CNTNAP2 gene in high functioning autism: no association according to family and meta-analysis approaches
  136. α2A -Adrenergic receptor polymorphisms and mRNA expression levels are associated with delay discounting in cocaine users
  137. Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction
  138. Serotonin Transporter and Tryptophan Hydroxylase Gene Variations Mediate Working Memory Deficits of Cocaine Users
  139. Region-specific regulation of the serotonin 2A receptor expression in development and ageing inpost mortemhuman brain
  140. Was können Biomarker heute leisten? Über den Einsatz von Biomarkern in der psychiatrischen Diagnostik am Beispiel der ADHS
  141. Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimer’s disease progression: CX3CL1, TREM2, and PPARγ
  142. Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette’s Syndrome and OCD
  143. Neurotrophin blood-based gene expression and social cognition analysis in patients with autism spectrum disorder
  144. Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer’s disease
  145. Was sind Omics?
  146. Prenatal stress increases the striatal and hippocampal expression of correlating c-FOS and serotonin transporters in murine offspring
  147. Aldehyde dehydrogenase (ALDH) in Alzheimer’s and Parkinson’s disease
  148. Imaging genetics in obsessive-compulsive disorder: Linking genetic variations to alterations in neuroimaging
  149. P.1.g.071 Interaction between serotonin 1A and 2A receptor subtypes in neuronal and lymphoblastoid cells
  150. Trio study and meta-analysis support the association of genetic variation at the serotonin transporter with early-onset obsessive–compulsive disorder
  151. Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study
  152. Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line
  153. Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line
  154. Copy Number Variation in Obsessive-Compulsive Disorder and Tourette Syndrome: A Cross-Disorder Study
  155. The neurobiological link between OCD and ADHD
  156. Wie biologisch sind Zwangsstörungen?
  157. Neuron-Specific Alterations in Signal Transduction Pathways associated with Alzheimer's Disease
  158. Extraordinarily Fast Response to Low-Dose Sertraline in a Child with Severe Obsessive-Compulsive Disorder and High Functioning Serotonin Transporter Genotype
  159. Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder
  160. Investigation of association of serotonin transporter and monoamine oxidase-A genes with Alzheimer's disease and depression in the VITA study cohort: A 90-month longitudinal study
  161. Aldehyde dehydrogenase 2 in sporadic Parkinson's disease
  162. Association study in siblings and case-controls of serotonin- and oxytocin-related genes with high functioning autism
  163. Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene
  164. Enhancement of cell viability after treatment with polyunsaturated fatty acids
  165. Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic Alzheimer´s Disease
  166. Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity
  167. The Loudness Dependence of Auditory Evoked Potentials (LDAEP) as an Indicator of Serotonergic Dysfunction in Patients with Predominant Schizophrenic Negative Symptoms
  168. 5-HT2A serotonin receptor agonist DOI alleviates cytotoxicity in neuroblastoma cells: Role of the ERK pathway
  169. Manifesto for a European research network into obsessive-compulsive and related disorders
  170. Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?
  171. Correction: Methylphenidate enhances neural stem cell differentiation
  172. Methylphenidate enhances neural stem cell differentiation
  173. S.08.03 New findings of copy number variations in OCD
  174. S.08.01 Potential biomarkers and genetic findings in ADHD
  175. Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study
  176. In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder
  177. Editorial
  178. Different effects of soluble and aggregated amyloid β42 on gene/protein expression and enzyme activity involved in insulin and APP pathways
  179. Pilot study: potential transcription markers for adult attention-deficit hyperactivity disorder in whole blood
  180. Alzheimer's disease and type 2 diabetes: Two diseases, one common link?
  181. Parkinson's disease: Molecular risk factors
  182. Inflammatory Pathways in Parkinson’s Disease; A BNE Microarray Study
  183. A molecular signature in blood identifies early Parkinson’s disease
  184. 1.12.1 PARKINSON'S DISEASE: MOLECULAR RISK FACTORS
  185. Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzymegene
  186. Altered mRNA expression of monoaminergic candidate genes in the blood of children with attention deficit hyperactivity disorder and autism spectrum disorder
  187. Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimer’s disease: The VITA and Milano studies
  188. d/l threo-methylphenidate enantiomers influence on catecholaminergic enzyme activities
  189. Pilot study on HTR2A promoter polymorphism, −1438G/A (rs6311) and a nearby copy number variation showed association with onset and severity in early onset obsessive–compulsive disorder
  190. Correlation of cognitive deficits and brain cholinesterase activity in streptozotocin-intracerebroventricularly treated rat model of sporadic alzheimer's disease
  191. Editorial
  192. Association of a Functional NOS1 Promoter Repeat with Alzheimer's Disease in the VITA Cohort
  193. Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats
  194. Brain tryptophan rather than pH-value is altered as consequence of artificial postmortem interval and storage conditions
  195. Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia
  196. Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease
  197. Effects of methylphenidate: the cellular point of view
  198. PGC-1 , A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
  199. Methyl- and acetyltransferases are stable epigenetic markers postmortem
  200. The link between iron, metabolic syndrome, and Alzheimer’s disease
  201. Diabetes Type II: A Risk Factor for Depression–Parkinson–Alzheimer?
  202. Increased Mitochondrial Aldehydedehydrogenase in the putamen of individuals with Alzheimer's disease
  203. Increased xanthine oxidase in the thalamus and putamen in depression
  204. Genetics of early-onset obsessive–compulsive disorder
  205. Can enzyme kinetics of prooxidants teach us a lesson about the treatment of Alzheimer's disease: A pilot post-mortem study
  206. Chronic exogenous corticosterone administration generates an insulin-resistant brain state in rats
  207. Modeling Sporadic Alzheimer's Disease: The Insulin Resistant Brain State Generates Multiple Long-Term Morphobiological Abnormalities Including Hyperphosphorylated Tau Protein and Amyloid-β
  208. Tryptophan is a marker of human postmortem brain tissue quality
  209. P.1.d.01l Multilevel phenotyping of NOS-I knockdown mice
  210. Stress and methylphenidate treatment, both modulate neuronal activity in an animal model for ADHD
  211. Potential gene expression biomarkers in whole blood of Alzheimer's disease
  212. pH measurement as quality control on humanpost mortembrain tissue: a study of the BrainNet Europe consortium
  213. Gene Expression as Peripheral Biomarkers for Sporadic Alzheimer's Disease
  214. Genetic risk factors and markers for Alzheimer’s disease and/or depression in the VITA study
  215. Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers
  216. Trabalho de consenso de força-tarefa da WFSBP sobre marcadores biológicos das demências: contribuição da análise do LCR e do sangue para o diagnóstico precoce e diferencial das demências
  217. Commonalities in the genetics of Alzheimer’s disease and Parkinson’s disease
  218. Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: A comparative post-mortem study
  219. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements
  220. P1-347: Biomarkers for Alzheimer's disease and depression in the Vienna Transdanube Aging (VITA) study
  221. Genomic aspects of sporadic Parkinson's disease
  222. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
  223. Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70
  224. Increased xanthine oxidase in the thalamus and putamen in depression
  225. Comparison Analysis of Gene Expression Patterns between Sporadic Alzheimer's and Parkinson's Disease
  226. The effect of methylphenidate treatment on the expression of synaptic vesicle proteins in a mouse model for Attention-Deficit/Hyperactivity Disorder
  227. Methylphenidate effects on cell growth and maturation in neuronal stem cells
  228. Alterations in Expression of Glutamatergic Transporters and Receptors in Sporadic Alzheimer's Disease
  229. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein
  230. Genes and Oxidative Stress in Sporadic and Familial Parkinsonism: cDNA Microarray Studies
  231. Gene and Protein Expression Profiling in Parkinson's Disease: Quest for Neuroprotective Drugs
  232. HIV Dementia: A Neurodegenerative Disorder with Viral Etiology
  233. 1.011 Early diagnosis for Parkinson's disease according to whole blood gene profile
  234. 1.100 Early diagnosis for Parkinson's disease according to whole blood gene profile
  235. Biostatistical analysis of gene microarrays reveals diverse expression clusters between macaque subspecies in brain SIV infection
  236. Association study of BDNF and CNTF polymorphism to depression in non-demented subjects of the “VITA” study
  237. Insulin resistant brain state: behavioural, neurochemical and genetical resemblance to sporadic Alzheimer's disease
  238. Estrogen Receptor ?? Gene (ESR??) 3???-UTR Variants in Alzheimer Disease
  239. Association Study of the 5-HTTLPR Polymorphism and Depression in 75-Year-Old Nondemented Subjects From the Vienna Transdanube Aging (VITA) Study
  240. Serotonin transporter polymorphism and LDL-cholesterol
  241. Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat
  242. The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice
  243. Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes
  244. Neuroprotective Strategies in Parkinson's Disease Using the Models of 6-Hydroxydopamine and MPTPa
  245. Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation
  246. Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70
  247. Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia
  248. Oxidative stress related markers in the “VITA” and the centenarian projects
  249. Genexpressionanalysen von Substantia-nigra-Gewebe Parkinson-Kranker
  250. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes
  251. Gene expression profile in streptozotocin rat model for sporadic Alzheimer?s disease
  252. The benefits of microarrays as tools for studying neuropsychiatric disorders
  253. Symposia
  254. Monoamine Oxidase-B Inhibition in Alzheimer's Disease
  255. Neuroprotective Strategies in Parkinson???s Disease
  256. Free radicals in Parkinson's disease
  257. Early and late molecular events in neurodegeneration and neuroprotection in Parkinson’s disease MPTP model as assessed by cDNA microarray; the role of iron
  258. Monoamin-Oxidase-Hemmer
  259. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine
  260. Molecular events in dopaminergic neurodegeneration and neuroprotection in MPTP model of Parkinson’s disease employing cDNA microarray Silvia Mandel, Edna Grünblatt, Yona Levites, Gila Maor, Moussa BH Youdim
  261. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss
  262. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies
  263. Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for Neuroprotection
  264. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson’s disease
  265. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine
  266. The Pivotal Role of Iron in NF-kappaB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators
  267. Apomorphine protects against MPTP-induced neurotoxicity in mice
  268. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity
  269. A hierarchical approach to vegetation classification in Kenya
  270. Behavioural and expressional phenotyping of nitric oxide synthase-I knockdown animals